Back to top

Image: Bigstock

Qiagen NV

Read MoreHide Full Article

Adverse foreign currency movement is a major headwind for QIAGEN. Furthermore, declining HPV sales in the U.S. continues to be a drag on overall sales of the company. Competitive landscape and strong reliance on collaborations also continue to be concerns. However, on a positive note, for the last three months, QIAGEN has been trading above the Zacks categorized Medical - Biomedical and Genetics industry. We are encouraged by the company's latest tie ups with Bristol-Myers Squibb and Maccura Biotechnology for futher development of NGS technology. QIAGEN also recently received license from The Johns Hopkins University for biomarkers to treat cancer. We are also looking forward to the company's recent FDA approvals for QFT-Plus and pre-market approval for its automated artus CMV QS-RGQ MDx kit. Moreover, its commitment to return more to its shareholders through increased share repurchases reflects its solid cash position.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


QIAGEN N.V. (QGEN) - free report >>

Published in